Context Therapeutics Inc.
Context Therapeutics Inc. (CNTX): 4 pipeline candidates · 2 upcoming catalysts · ~15 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.6 months
D/E 0.13 · 4% dilution
Lead: Phase 2
4 candidates
2 upcoming, next in ~75d
N/A
A transparent, data-derived signal for Context Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$55.3M
Cash
$54.5M
Quarterly Burn
$11.4M
Runway
14.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$150.8M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 10,679,391 | $28.0M |
| avidity partners management lp | 9,996,534 | $24.9M |
| deep track capital, lp | 7,419,355 | $19.4M |
| vanguard capital management llc | 6,863,906 | $18.0M |
| franklin resources inc | 3,803,338 | $10.0M |
| marshall wace, llp | 2,948,441 | $7.7M |
| tcg crossover management, llc | 2,682,696 | $7.0M |
| great point partners llc | 2,238,496 | $5.9M |
| millennium management llc | 1,424,374 | $3.7M |
| squadron capital management llc | 1,100,000 | $2.9M |
Showing top 10 of 56 institutional holders of Context Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Context Therapeutics Inc.'s pipeline?
Context Therapeutics Inc. (CNTX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Context Therapeutics Inc.'s lead drug candidate?
Context Therapeutics Inc.'s most advanced tracked candidate is CT-202 (Phase 1) for Solid tumors including bladder, colorectal, lung and breast.
What is Context Therapeutics Inc.'s next catalyst?
Context Therapeutics Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Part" — expected September 1, 2026.
What is Context Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Context Therapeutics Inc. has approximately 14.6 months of cash runway.
What is Context Therapeutics Inc.'s market capitalization?
Context Therapeutics Inc.'s market capitalization is approximately $55.3M.
Get the full picture on Context Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.